|
Post by saxcmann on Apr 27, 2017 11:14:56 GMT -5
Just noticed that Fidelity rate on lending is now 31.5% so there is mounting pressure. But today its not worth being in that program. I don't think retail investors move the needle but at this time why even play the game. Just to confirm 31.5% is lending rate for shorts. So about 20% for retailer loaning shares.
|
|
|
Volume too
Apr 21, 2017 12:04:54 GMT -5
via mobile
Post by saxcmann on Apr 21, 2017 12:04:54 GMT -5
Stock has been trading this week as to we are going to hear some very negative news in the next few days ... My gentleman's bet is on AH news. My bet is no news. What negative news could come?...too early for bankruptcy news?
|
|
|
Post by saxcmann on Apr 19, 2017 11:39:27 GMT -5
• $55.0 million principal amount of 2019 notes bearing interest at 9.75% per annum, $15.0 million of which is due and payable in July 2017, $15.0 million of which is due and payable in July 2018 and $25.0 million of which is due and payable in July and December 2019; To July of 2018? I didn't mean debt payments were kicked down the road. Cash runway. 2 more months gets us to the "ultra" label decision by fda. Do things change if mnkd has only ultra label insulin?? Would someone be interesting in buying mnkd? Would docs prescribe more?
|
|
|
Post by saxcmann on Apr 11, 2017 20:36:28 GMT -5
I think you know the label forwards and back wards, and if I didn't know better you could be a bot. I really wanted to know if you secretly had afrezza lust in your heart.
If I look deep, why isn't it working for some? All I can think of is those individuals, their liver? Insulin resistance? Or they were dosing like subq, under dosing for afrezza.
Al Mann seems like a brain. He knew this drug. Unbelievable he knew.
I would really like a digital noninvasive glucose monitor watch.
Perhaps... Education that was lacking from their healthcare provider combined with lack of interest or ability to figure it out on their own. If everyone were really motivated and had basic analytical inclination, it probably wouldn't matter that many healthcare providers have not really understand Afrezza... but in the real world a lot of people are at best going to do what their doctors tell them to do. Amen! Exactly!
|
|
|
Ripano
Apr 10, 2017 12:40:32 GMT -5
via mobile
Post by saxcmann on Apr 10, 2017 12:40:32 GMT -5
Regardless of why the numbers were wrong, I'm appreciative of Ripano's weekly service to us all in keeping us informed of the numbers. He's been spot on week after week, so I think he's more than earned a pass on one mistake, no matter the circumstances. I'll be honest and say that I bought into the hype and bought a few thousand more shares believing the numbers were real. It brought my average down at least, but I threw good money after bad and ended up regretting it Seeing that the execs of the company also have golden parachutes in place, to me, wasn't very comforting either. One can only hope that if things end up in court, a good judge would throw that out and they'd suffer like the rest of us. I did the same silent. As Liane said I won't hold it against him but i will take more caution in trusting his numbers fully...I will use this analogy, if your wife cheats on you, are you going to ever fully trust her again? You might forgive her but will you ever fully trust her? Probably not...
|
|
|
Post by saxcmann on Apr 7, 2017 17:14:24 GMT -5
The Mann Group will have the final say, but I'm hoping someone there is as fed up as the rest of us and exercises some authority. I have reason to believe they are...
|
|
|
Post by saxcmann on Apr 7, 2017 9:20:17 GMT -5
Ripano accidentally posted the wrong numbers (Feb monthly), see new ones in charts. Too good to be true!
|
|
|
Post by saxcmann on Apr 4, 2017 13:15:45 GMT -5
The truth about Afrezza is that you can take more of it without as much concern about going hypo ... and get better control. [/p]
I believe Afrezza is ahead of its time or something... not sure.. and the trial data we have didn't support superiority... nor does the label give us the freedom to say what Afrezza really is... or how to dose.. I have said this from the beginning...
But to say it doesn't work is completely false.. it is the hands down the best insulin on the market.
[/quote] My endo friend said your exact comments about dosing aggressively without hypos and more control. It's true and your comments about trial data with fda has handcuffed what mnkd can do and say with label limitations. Add slow insurance coverage and misinformed docs and you see why sales suck. 'Ultra' label should help a little, if we can make it that long...fda in no hurry and we need more money soon!
|
|
|
Post by saxcmann on Apr 3, 2017 16:34:51 GMT -5
I would take 300 scripts this Friday.
|
|
|
Post by saxcmann on Apr 1, 2017 9:37:36 GMT -5
Fanz: Not sure where you got your numbers from or if you are just stirring the FUD pot. So for you and anyone else that cares, here are some rough numbers for Breakeven. Current Burn Rate: 10M / month Annual Burn Rate: 120M 30 Day Patient Cost: 600 Profit to Mannkind: 150 30d Prescriptions Required for breakeven: 120M/150 = 800K 90d Prescriptions Required: 267k (annually) Weekly TRX Required: 267 / 52 = 5128 Roughly speaking MNKD needs 5200 total prescription per week to break even at current price structure. This corresponds to approximately 67700 patients using Afrezza. Note: Danbury plant with 3 lines has current max capacity of 500k annual patients. OOG Thanks. So most precsxriptions are 90 days? Otherwise we need more? Castagna: There are over 22M Type 1 and Type 2 people with diabetes who are in treatment and over 4 Million of them are on meal-time insulin. The average territory has over 55,000 insulin prescriptions in their territory per quarter. Kam: Are they concentrated in a particular geographic area or are they spread out nationwide? Castagna: They are extremely focused in key markets that will directly impact ~50% of the meal-time insulin market and indirectly impact another 10-20%. I'll take 1%...🤔
|
|
|
Post by saxcmann on Mar 28, 2017 10:05:20 GMT -5
I'm quite interested in what exactly has changed in the two weeks since q4 earnings were announced to bring on this extremely negative sentiment. Were you expecting much better scripts? The PPS decline? Did something else happen? There hasn't been any changes and the market sees that as inherently negative. MNKD expected increases in scripts. There hasn't been, and all the while, they're burning $10 million per month on a dwindling cash reserve. Even if the sales team can deliver massive script sales in short order (they won't) the company will run out of money before it's profitable. I'm suspect that any decent financing will come along, so that leaves the company with two viable options...1) dilute existing shareholders in a massive way to generate more money, or 2) file Chapter-11/Chapter-7. It's folly to believe that a partnership or buyout is coming, so there are no other viable sources of income. They can't sell their drug, as they've demonstrated, so the remaining options destroy shareholders either way. I'd get out now, but honestly the pennies I'd get out of it is insignificant to me. I've already lost it all. Might as well wait and pray for a hail mary. Exactly!!!
|
|
|
Post by saxcmann on Mar 28, 2017 10:00:04 GMT -5
Sports: I feel your frustration. I hope you will post more I look for your post because they are informed and interesting. My money is gone, or it is on paper. At this point I'm not even thinking about it. I have to focus on making money in other stocks. I had a investor tell me he was scared to death to buy another stock. Really? Just pick one. They're almost all going up! My frustration comes from knowing how worried the people that are on Afrezza are. They can't imagine life with out it! The company as we all know has to do something to stabilize it's self. People are under so much stress. Al Mann once again built the better mousetrap...But almost nobody knows! I feel ya sports. Lost hundreds of thousands on paper. So sad knowone knows about afrezza and it cost so much. Hope PWD who discovered afrezza can stay on it.
|
|
|
Post by saxcmann on Mar 26, 2017 21:15:44 GMT -5
"[O]ur big prescribers that really loved Afrezza did not come back on Board. And in fact, one of them passed away unfortunately, and that did hurt the Q4 performance." That doesn't make any sense? If they really loved Afrezza why aren't they on board? And why didn't they know right away and correct it? And what patient would drop the drugs they are on because their doctor died? The new rep that handles that area will know who the doctor referred his patients to and make sure the new doc is up to speed. And I'm sure they are working like crazy getting the others back on board. And while I'm at it... I have another question for anyone who wants to answer:-) Are we sure the patients are being told to use a follow up dose? And that people have to buy more Afrezza because of it? ( Fine with me if that's how to get the best results.) Tom's kids don't do that very often. They are not afraid to take enough. And don't need extra. But they are also not trying to be perfect or compete with their numbers. And are the T2's needing more also? I suspect Big Pharma is putting a great deal of pressure on the doctors not to use afrezza. The amount of pressure they put on the FDA not to approve was amazing. Unless they are properly dosing their A1c results won't be better than an RAA so its easy for the doctor to change them back to an RAA. I fully suspect most patients have never been explained first and second phase insulin release. Why would they? Until afrezza there was no drug which could provide a phase one release. Most doctors probably do not understand how important it is to keep harmony in not only turning off sugar production by the liver but to also blunt the glucose rise to prevent temporary insulin resistance from high BG. The last thing Big Pharma wants to mention is the importance of first phase release. If they did they would all be promoting afrezza which would not be good for them. To answer your question about T2s needing more, the short answer is they too would need a second phase release - second dose, depending on initial dose and depending on the fat/carb composition of the meal - same as a T1. There is no difference between a T1 and T2 in this regard. The key is, is their liver working properly. If they are taking metformin it is not. If it is unless they really overdose the liver will kick in and keep them from hypos. You can see this in the patent application but even with metformin only 2% had hypo issues. The big problem is the T2's BG in some cases has been too high for so long, they have developed higher insulin resistance and need higher doses of insulin vs. the typical T1. But, if that T1 is managing to the ACCORD recommendation they too will need more after awhile as the body adjusts to the higher BG. This is often referred to as the honeymoon phase by new T1s. After about 6 months they need more insulin, no kidding but if they had been using afrezza and keeping their fasting BG under 100 they wouldn't. Afrezza is so different from anything current doctors and insulin users have encountered they really have a hard time believing to just "Go Big" with the dose and don't worry. They have allows been taught and learned the hard way the Analogs are dangerous and R insulin is dangerous. Accurate sayhey. Especially the last paragraph. You can dose afrezza aggressively. Most docs are misinformed and don't understand dosing. Highly recognized top docs need to be "paid off" to promote/educate/speak about afrezza like BP does with their drugs. Mnkd doesn't have the money.
|
|
|
Post by saxcmann on Mar 24, 2017 14:50:19 GMT -5
What great news for those who continue to lend shares to short sellers who together with the MM's, and big pharmas, continue to undermine Mannkind's continued existence. I say a hearty Well done! Comes down to scripts at this point. Nothing else. Sorry, retailers lending shares have no influence on stock price.
|
|
|
Post by saxcmann on Mar 17, 2017 10:31:42 GMT -5
You and I both know it's too early to decide if the new sales team is making headway. Next 8 weeks will be crucial for mnkd to increase scripts. If not numbers don't lie...agree By headway do you mean achieving what half the sales force achieved before? I dont call that an improvement. Because 10 weeks into 2017 they cant even do that. Headway=week over week increases. Get close to Sanofi numbers and we got doors opening...
|
|